Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

M Solmi, M De Toffol, JY Kim, MJ Choi, B Stubbs… - bmj, 2023 - bmj.com
Objective To systematically assess credibility and certainty of associations between
cannabis, cannabinoids, and cannabis based medicines and human health, from …

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

O Devinsky, MR Cilio, H Cross, J Fernandez‐Ruiz… - …, 2014 - Wiley Online Library
To present a summary of current scientific evidence about the cannabinoid, cannabidiol
(CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders …

Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial

P McGuire, P Robson, WJ Cubala… - American Journal of …, 2018 - Am Psychiatric Assoc
Objective: Research in both animals and humans indicates that cannabidiol (CBD) has
antipsychotic properties. The authors assessed the safety and effectiveness of CBD in …

Cannabidiol: pharmacology and therapeutic targets

SC Britch, S Babalonis, SL Walsh - Psychopharmacology, 2021 - Springer
Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …

New trends in cannabis potency in USA and Europe during the last decade (2008–2017)

S Chandra, MM Radwan, CG Majumdar… - European archives of …, 2019 - Springer
Through the potency monitoring program at the University of Mississippi supported by
National Institute on Drug Abuse (NIDA), a total of 18108 samples of cannabis preparations …

[HTML][HTML] Cannabidiol as a potential treatment for anxiety disorders

EM Blessing, MM Steenkamp, J Manzanares… - …, 2015 - Elsevier
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum
drug that in recent years has drawn increasing interest as a treatment for a range of …

An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies

K Iffland, F Grotenhermen - Cannabis and cannabinoid research, 2017 - liebertpub.com
Introduction: This literature survey aims to extend the comprehensive survey performed by
Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from …

Acute and chronic effects of cannabinoids on human cognition—a systematic review

SJ Broyd, HH Van Hell, C Beale, M Yuecel… - Biological psychiatry, 2016 - Elsevier
Cannabis use has been associated with impaired cognition during acute intoxication as well
as in the unintoxicated state in long-term users. However, the evidence has been mixed and …

[HTML][HTML] Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

FM Leweke, D Piomelli, F Pahlisch, D Muhl… - Translational …, 2012 - nature.com
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but
moderately inhibits the degradation of the endocannabinoid anandamide. We previously …

Diversity of molecular targets and signaling pathways for CBD

DL de Almeida, LA Devi - Pharmacology research & …, 2020 - Wiley Online Library
Cannabidiol (CBD) is the second most abundant component of the Cannabis plant and is
known to have effects distinct from Δ9‐tetrahydrocannabinol (THC). Many studies that …